Every Member of 23andMe's Board Except the CEO Just Resigned in Disgust
After a years-long valuation free-for-all, nearly the entire board of directors for 23andMe has resigned — a move that apparently was news to its overly-optimistic chief executive. Earlier this week,
23andMe Board Resigns in New Blow to DNA-Testing Company
All seven independent directors of DNA-testing company 23andMe resigned, following a protracted negotiation with CEO Anne Wojcicki over her plan to take the company private.
23andMe board quits over plans to take DNA testing company private
All seven independent directors of 23andMe’s board resigned on Tuesday, citing disagreements over the chief executive’s plan to take the company private. The departures leave just one
23andMe independent board resigns in feud over CEO Anne Wojcicki’s plan to take company private
All seven of 23andMe’s independent board members resigned in a stinging rebuke to a proposal by CEO Anne Wojcicki’s plans to to take the company private. Wojcicki, who has been trying to take the company private since April, proposed to acquire all outstanding shares of 23andMe not owned by her or her affiliates for $0.40 per share, in July.
Every single member of the board just resigned from DNA tester 23andMe
Following a monthslong battle over CEO Anne Wojcicki’s plans to take 23andMe private, all seven independent members of its board resigned en masse Tuesday. The move is almost certainly the final nail in the coffin for the embattled company known for its mail-order DNA-testing kit.
Turmoil strikes 23andMe as board members resign in dispute with founder
The pioneering DNA testing firm has been struggling to stay afloat financially despite ambitious ventures to provide health care and develop pharmaceuticals.
Board Members Resign En Masse at 23andMe (NASDAQ:ME)
The stock of 23andMe has a consensus Moderate Buy rating based on the views of two Wall Street analysts. One analyst rates the stock a Buy and the other rates it a Hold. There are no Sell ratings currently. The average price target of $1.21 per share implies potential upside of 260.76% from where the shares currently trade.
Independent directors resign from 23andMe board after opposing move to privatize
The seven independent members of the board of personal genomics company 23andMe quit Tuesday amid opposition to CEO Anne Wojcicki’s plan to take the company private.
Read the memo 23andMe's cofounder sent to staff after the entire board quit
Me's entire board of directors resigned over cofounder and CEO Anne Wojcicki's ongoing plan to take it private.
What happened to 23andMe?
The history of the DNA-testing startup reads like a checklist of Silicon Valley clichés: founder squabbles, gobs of cash, a ...
Science Daily3d
Ancient DNA News
with a pubic hip bone the size of a 'dinner plate', has been described in a new ... The Plague May Have Caused the Downfall of the Stone Age Farmers July 10, 2024 — Ancient DNA from bones and ...
TweakTown13d
Telegram CEO claims to have fathered more than 100 children, plans to 'open-source' his DNA
Pavel Durov, the Russian billionaire who founded Telegram, has claimed to have helped father more than 100 children through ...
CoinTelegraph16d
Stop giving your DNA data away for free to 23andMe, says Genomes.io CEO
What is the value of DNA data? According to genetic testing companies ... According to Aldo de Pape, co-founder and CEO of Genomes.io — a privacy-focused alternative to 23andMe — there is ...
Wall Street Journal3d
23andMe Board Resigns in New Blow to DNA-Testing Company
All seven independent directors of DNA-testing company 23andMe ME-0.29%decrease; red down pointing triangle resigned Tuesday, following a protracted negotiation with founder and Chief Executive ...